Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 320

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

Open access
Gavin, Patrick G., Colangelo, Linda H., Fumagalli, Debora, Tanaka, Noriko, Remillard, Matthew Y., Yothers, Greg, Kim, Chungyeul, Taniyama, Yusuke, Kim, Seung Il, Choi, Hyun Joo, Blackmon, Nicole L., Lipchik, Corey, Petrelli, Nicholas J., O'Connell, Michael J., Wolmark, Norman, Paik, Soonmyung, Pogue-Geile, Kay L.·2012·Clinical Cancer Research

Abstract

Purpose: The purpose of this study was to examine the prognostic and oxaliplatin predictive value of mismatch repair (MMR) status and common hot spot mutations, which we previously identified in stage II and III colon cancer. Experimental Design: Mutations in BRAF, KRAS, NRAS, MET, and PIK3CA were profiled in 2,299 stage II and III colon tumors from National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials C-07 (n = 1,836) and C-08 (n = 463) with Type Plex chemistry and mass spectrometry. C-07 tested the worth of adding oxaliplatin to 5-fluorouracil plus leucovorin, and C-08 tested the worth of adding bevacizumab to FOLFOX. Cox proportional hazard models were used to assess prognostic or oxaliplatin predictive value of mutations for tumor recurrence, overall survival (OS), and survival after recurrence (SAR). Results: BRAF mutations were associated with MMR-deficient tumors (P < 0.0001), poor OS [HR, 1.46; 95% confidence interval (CI), 1.20–1.79; P ≤ 0.0002], and poor SAR (HR, 2.31; 95% CI, 1.83–2.95; P < 0.0001). Mutations in KRAS, NRAS, MET, and PIK3CA were not associated with recurrence, OS, or SAR. MMR-deficient tumors were associated with an improved prognosis based on recurrence (HR, 0.48; 95% CI, 0.33–0.70; P < 0.0001). Mutations and MMR status were not predictive for oxaliplatin benefit. Conclusions: This study shows that BRAF mutations profiled from stage II and III colon cancer tumors were associated with poor SAR and validates and explains, at least in part, previous observations associating it with poor OS. Profiling of all of these mutations is warranted for future clinical trials testing new targeted therapies that block relevant signaling pathways. Such clinical trials are under development at NSABP. Clin Cancer Res; 18(23); 6531–41. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-0605

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 320

Metadata

Authors
Gavin, P. G., Colangelo, L. H., Fumagalli, D., Tanaka, N., Remillard, M. Y., Yothers, G., Kim, C., Taniyama, Y., Kim, S. I., Choi, H. J., Blackmon, N. L., Lipchik, C., Petrelli, N. J., O'Connell, M. J., Wolmark, N., Paik, S., & Pogue-Geile, K. L.
Venue
Clinical Cancer Research
Published
2012-11-29
Volume
18
Issue
23
Pages
6531-6541
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2111807726
Cited by
320
References
46
FWCI
11.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-0605
The paper
Gavin, P. G., Colangelo, L. H., Fumagalli, D., Tanaka, N., Remillard, M. Y., Yothers, G., Kim, C., Taniyama, Y., Kim, S. I., Choi, H. J., Blackmon, N. L., Lipchik, C., Petrelli, N. J., O'Connell, M. J., Wolmark, N., Paik, S., & Pogue-Geile, K. L. (2012). Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-0605

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.